Scancell

"Oxford, U.K.-based Scancell’s vaccine candidates are designed to trigger T-cell responses against both the spike protein, the target of all approved prophylactics, and the nucleocapsid protein. By inducing immunity against the two proteins, including the conserved nucleocapsid, Scancell is aiming to provide protection against future variants and other SARS-CoV viruses. "